208 related articles for article (PubMed ID: 23496667)
21. Different spectra of therapeutic vaccine development against HPV infections.
Bolhassani A; Mohit E; Rafati S
Hum Vaccin; 2009 Oct; 5(10):671-89. PubMed ID: 19684468
[TBL] [Abstract][Full Text] [Related]
22. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
23. Origin and immunoescape of uterine cervical cancer.
Van Hede D; Langers I; Delvenne P; Jacobs N
Presse Med; 2014 Dec; 43(12 Pt 2):e413-21. PubMed ID: 25448124
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
25. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
26. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
27. Prospects for therapeutic HPV vaccines.
Trimble CL
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S249-50. PubMed ID: 16419216
[No Abstract] [Full Text] [Related]
28. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
29. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection.
Asiaf A; Ahmad ST; Mohammad SO; Zargar MA
Eur J Cancer Prev; 2014 May; 23(3):206-24. PubMed ID: 24129107
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
31. Vaccines against human papillomavirus.
Lin YY; Alphs H; Hung CF; Roden RB; Wu TC
Front Biosci; 2007 Jan; 12():246-64. PubMed ID: 17127297
[TBL] [Abstract][Full Text] [Related]
32. Antigen-specific immunotherapy of cervical and ovarian cancer.
Hung CF; Wu TC; Monie A; Roden R
Immunol Rev; 2008 Apr; 222():43-69. PubMed ID: 18363994
[TBL] [Abstract][Full Text] [Related]
33. [Advances in human papillomavirus therapeutic vaccine].
Liu B; Zhao QZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):685-90. PubMed ID: 18051729
[TBL] [Abstract][Full Text] [Related]
34. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
Cheng MA; Farmer E; Huang C; Lin J; Hung CF; Wu TC
Hum Gene Ther; 2018 Sep; 29(9):971-996. PubMed ID: 29316817
[TBL] [Abstract][Full Text] [Related]
36. Current research into novel therapeutic vaccines against cervical cancer.
Cordeiro MN; De Lima RCP; Paolini F; Melo ARDS; Campos APF; Venuti A; De Freitas AC
Expert Rev Anticancer Ther; 2018 Apr; 18(4):365-376. PubMed ID: 29475377
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
38. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
39. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
40. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
Front Immunol; 2018; 9():3000. PubMed ID: 30619353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
